Nilotinib
4 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.
Trials
4
Ongoing
0
Recruiting
0
Completed
3
Sites
2
Countries
1
Endpoints
45
Composite endpoints
0
Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 45 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.
Development
Where the program stands
Trials by phase
Trials by status
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Most-measured metrics
Top 20 metrics across this asset's endpoints
Normalized metric codes are available for 15 of 45 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.
3
3
2
2
2
2
1
Trials
Trials for this asset
Every trial for this asset, with the same search, filters, and sort as the Trials tab.
4 of 4
| Asset / Disease area | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| NCT04002674Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Dementia With Lewy Bodies | Nilotinib Lewy body dementia | Dementia with Lewy bodies | Ph 2 | Completed | 1 | Apr 2025 | 1 | results |
| NCT02281474Nilotinib in Cognitively Impaired Parkinson Disease Patients 001 | Nilotinib Lewy body dementia | MMSE 23-30 | Ph 1 | Completed | 1 | May 2015 | 1 | |
| ADImpact of Nilotinib on Safety, Biomarkers and Clinical Outcomes in Mild to Moderate Alzheimer's Disease | Nilotinib Alzheimer’s disease | mild-to-moderate AD | Ph 2 | Completed | 1 | Dec 2020 | 2 | |
| NILEADEvaluating the Efficacy and Safety of Nilotinib BE in Subjects With Early Alzheimer's Disease | Nilotinib Alzheimer’s disease | Alzheimer's disease | Ph 3 | Unknown | 0 | Dec 2025 | 1 |
Showing 1-4 of 4 trials